Quick evaluation of kinase inhibitors by surface plasmon resonance using single-site specifically biotinylated kinases

Journal of Biomolecular Screening

Volumn 19, Issue 3, 2014, Pages 453-461

  Kitagawa, Daisuke ^a   Gouda, Masaki ^a   Kirii, Yasuyuki ^a  

^a 1 5 5 Minatojima Minamimachi   (Japan)

Author keywords

biotinylation; drug discovery; kinase inhibitor; surface plasmon resonance; tyrosine kinase

Indexed keywords

BRUTON TYROSINE KINASE; COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; DASATINIB; LAPATINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STAUROSPORINE; SUNITINIB; UNCLASSIFIED DRUG;

ARTICLE; BIOTINYLATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME ASSAY; ENZYME INHIBITION; ENZYME KINETICS; IC 50; NUCLEOTIDE SEQUENCE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE;

BIOTINYLATION; DRUG DISCOVERY; KINASE INHIBITOR; SURFACE PLASMON RESONANCE; TYROSINE KINASE;

ANIMALS; BIOTINYLATION; CELL LINE; DRUG DISCOVERY; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION; GENE ORDER; GENETIC VECTORS; PHOSPHOTRANSFERASES; SURFACE PLASMON RESONANCE;

EID: 84893873004     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057113506051     Document Type: Article

References (18)

1. Cohen P. Protein Kinases: The Major Drug Targets of the Twenty-first Century?. Nat. Rev. Drug Discov. 2002 ; 1: 309-315
2. Force T., Kolaja K. L. Cardiotoxicity of Kinase Inhibitors: The Prediction and Translation of Preclinical Models to Clinical Outcomes. Nat. Rev. Drug Discov. 2011 ; 10: 111-126
3. Copeland R. A., Pompliano D. L., Meek T. D. Drug-Target Residence Time and Its Implications for Lead Optimization. Nat. Rev. Drug Discov. 2006 ; 5: 730-739
4. Duffy S., Tsao K. L., Waugh D. S. Site-Specific, Enzymatic Biotinylation of Recombinant Proteins in Spodoptera frugiperda Cells Using Biotin Acceptor Peptides. Anal. Biochem. 1998 ; 262: 122-128
5. Schatz P. J. Use of Peptide Libraries to Map the Substrate Specificity of a Peptide-Modifying Enzyme: A 13 Residue Consensus Peptide Specifies Biotinylation in Escherichia coli. Biotechnology (NY). 1993 ; 10: 1138-1143
6. Lombardo L. J., Lee F. Y., Chen P., et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2- methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays. J. Med. Chem. 2004 ; 47: 6658-6661
7. Sun L., Liang C., Shirazian S., et al. Discovery of 5-[5-fluoro-2-oxo-1, 2- dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase. J. Med. Chem. 2003 ; 46: 1116-1119
8. Kitagawa D., Yokota K., Gouda M., et al. Activity-Based Kinase Profiling of Approved Tyrosine Kinase Inhibitors. Genes Cells. 2013 ; 18: 110-122
9. Kinoshita T., Miyano N., Nakai R., et al. Protein Purification and Preliminary Crystallographic Analysis of Human Lyn Tyrosine Kinase. Protein Expr. Purif. 2008 ; 58: 318-324
10. Marttila A. T., Laitinen O. H., Airenne K. J., et al. Recombinant NeutraLite Avidin: A Non-glycosylated, Acidic Mutant of Chicken Avidin That Exhibits High Affinity for Biotin and Low Non-specific Binding Properties. FEBS Lett. 2000 ; 467: 31-36
11. Wood E. R., Truesdale A. T., McDonald O. B., et al. A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib): Relationships among Protein Conformation, Inhibitor Off-Rate, and Receptor Activity in Tumor Cells. Cancer Res. 2004 ; 64: 6652-6659
12. Liu Y., Gray N. S. Rational Design of Inhibitors That Bind to Inactive Kinase Conformations. Nat. Chem. Biol. 2006 ; 2: 358-364
13. Karaman M. W., Herrgard S., Treiber D. K., et al. A Quantitative Analysis of Kinase Inhibitor Selectivity. Nat. Biotechnol. 2008 ; 26: 127-132
14. Uitdehaag J. C. M., Sünnen C. M., Doornmalen A. M. V., et al. Multidimensional Profiling of CSF1R Screening Hits and Inhibitors: Assessing Cellular Activity, Target Residence Time, and Selectivity in a Higher Throughput Way. J. Biomol. Screen. 2011 ; 16: 1007-1017
15. Anderson K., Lai Z., McDonald O. B., et al. Biochemical Characterization of GSK1070916, a Potent and Selective Inhibitor of Aurora B and Aurora C Kinases with an Extremely Long Residence Time. Biochem. J. 2009 ; 420: 259-265
16. Hantschel O., Rix U., Schmidt U., et al. The BTK Tyrosine Is a Major Target of the Bcr-Abl Inhibitor Dasatinib. Proc. Natl. Acad. Sci. U. S. A. 2007 ; 104: 13283-13288
17. Marcotte D. J., Liu Y. T., Arduini R. M., et al. Structures of Human Bruton's Tyrosine Kinase in Active and Inactive Conformations Suggest a Mechanism of Activation for TEC Family Kinases. Protein Sci. 2010 ; 19: 429-439
18. Navratilova I., Macdonald G., Robinson C., et al. Biosensor-Based Approach to the Identification of Protein Kinase Ligands with Dual-Site Modes of Action. J. Biomol. Screen. 2012 ; 17: 183-193